Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

smart watch

- PMLiVE

Roche’s Perjeta on US fast-track for early breast cancer

FDA grants priority review for drug's use before surgery

- PMLiVE

FDA forces Achillion to delay hepatitis C programme

Abnormal liver functions detected in some patients taking sovaprevir

- PMLiVE

Setback for Merck & Co as FDA knocks back insomnia drug

US regulator asks for company to file for approval of a lower starting dose of suvorexant

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

- PMLiVE

US FDA nets $41m of illegal medicines in online pharmacy crackdown

Regulator shuts down 1,677 sites in global operation

- PMLiVE

Sanofi CEO Viehbacher to head EFPIA

Assumes presidency at European trade body

- PMLiVE

Eisai pulls epilepsy drug Fycompa in Germany

Based on unfavourable assessment by pricing body

- PMLiVE

ADA: Sanofi eyes 2014 submissions for Lantus successor

Releases first phase III data for U300 formulation of insulin glargine

- PMLiVE

US FDA approves Vibativ for lung infection caused by MRSA

Theravance’s drug backed to treat hospital-acquired bacterial pneumonia

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

Novartis building

US FDA deems Novartis’ heart failure candidate a ‘breakthrough’

Serelaxin demonstrates ability to reduce shortness of breath and lower chance of dying

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links